Summary & Overview
HCPCS J9050: Injection, Carmustine 100 mg
HCPCS Level II code J9050 denotes the injection of carmustine, 100 mg, a cytotoxic chemotherapy agent used in cancer care. Nationally, accurate billing of chemotherapeutic agents like carmustine is important for clinical documentation, payer adjudication, and cost transparency in oncology services. This code is primarily billed for outpatient infusion episodes in hospital-based infusion centers and oncology clinics where parenteral chemotherapy is administered.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national benchmarks for utilization and reimbursement patterns, common billing modifiers and service line considerations, and clinical context relevant to chemotherapy drug coding. The publication also outlines payer policies that influence coverage and prior authorization practices and highlights documentation elements that support claim adjudication.
The analysis provides concise takeaways for coding accuracy, claims processing, and administrative workflows related to parenteral chemotherapy billing. Data not available in the input is noted where applicable, and the report focuses on nationwide payer practices and policy impacts rather than state-specific guidance.
Billing Code Overview
HCPCS Level II code J9050 describes the injection of carmustine, 100 mg. This code represents a single-dose pharmaceutical administration of carmustine, an alkylating chemotherapy agent used in oncologic treatment regimens.
Service Type: Chemotherapy drug administration
Typical Site of Service: Hospital outpatient infusion center or oncology clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a primary or metastatic brain tumor, glioma, or other malignancy for which systemic or intracavitary chemotherapy with carmustine is indicated. The patient presents to an outpatient oncology infusion clinic or hospital infusion center for administration of J9050 (injection, carmustine, 100 mg). Prior to the encounter, the oncologist documents diagnosis, planned dose, route (intravenous or intracavitary during neurosurgical procedure), allergies, recent labs (CBC, liver and renal function), and informed consent. On the day of service, nursing performs pre-medication assessment, verifies chemotherapy orders, obtains venous access (peripheral IV or central venous catheter), prepares the drug in an appropriate sterile compounding area per USP <797>/<800>, and administers carmustine according to protocol with vital sign monitoring and appropriate supportive medications. Post-infusion monitoring includes observation for myelosuppression, pulmonary toxicity, hepatic dysfunction, and local site reactions. If carmustine is administered in conjunction with neurosurgery (e.g., wafer implantation of biodegradable carmustine polymers), billing of J9050 may occur for systemic or local dose accounting depending on facility policy and documentation provided by the surgical team. Typical sites of service are outpatient infusion centers, hospital outpatient departments, inpatient hospital settings, and perioperative operating rooms when given intracavitary during tumor resection.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|